Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel
NASDAQ:KRYS

Krystal Biotech Q2 2026 Earnings Report

Krystal Biotech logo
$375.40 +6.80 (+1.84%)
Closing price 04:00 PM Eastern
Extended Trading
$379.00 +3.60 (+0.96%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Krystal Biotech EPS Results

Actual EPS
N/A
Consensus EPS
$1.80
Beat/Miss
N/A
One Year Ago EPS
N/A

Krystal Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
$123.83 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Krystal Biotech Announcement Details

Quarter
Q2 2026
Date
8/3/2026
Time
Before Market Opens
Conference Call Date
Monday, August 3, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Krystal Biotech Earnings Headlines

John Charles Thomas Sells 1,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock
June 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30866533
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)
June 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/krystal-biotech-announces-positive-interim-120010426.html
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
July 8 at 1:00 AM  |  Porter & Company (Ad)
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream
June 24, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/the-brown-capital-management-small-company-fund-bets-on-krystal-biotech-krys-for-its-resilient-revenue-stream-1788382/
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream
June 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/brown-capital-management-small-company-135513502.html
Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?
June 7, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-krystal-biotech-inc-krys-a-good-stock-to-buy-now-1770930/
See More Krystal Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Krystal Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Krystal Biotech and other key companies, straight to your email.

About Krystal Biotech

Krystal Biotech (NASDAQ:KRYS) is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition. KB103 has advanced through clinical trials under orphan drug and breakthrough therapy designations granted by the U.S. Food and Drug Administration. In addition to DEB, Krystal Biotech is advancing a second program, KB105, aimed at correcting the genetic defect underlying pseudoxanthoma elasticum. The company maintains an in-house cGMP manufacturing facility to support both development activities and future commercialization efforts.

Since its initial public offering on the Nasdaq in July 2019, Krystal Biotech has expanded its clinical and regulatory footprint, enrolling patients in multiple U.S. and international study sites. The company is led by a management team with deep expertise in gene therapy development and regulatory strategy. With a growing pipeline and a dedicated manufacturing infrastructure, Krystal Biotech is positioned to advance its targeted gene therapies through late-stage development and toward potential approval.

View Krystal Biotech Profile
Earnings Tools